Big Pharma and some financial services companies could be hurt by midterms: Beacon Policy's Myrow
Speakers
Stephen Myrow
— Founder, Beacon Policy Advisors
Summary
Stephen Myrow of Beacon Policy Advisors argues that if Democrats take at least one chamber in the midterms, they will pursue a second oversight track through the private sector, targeting companies with Trump ties and broad voter anger. He says investors should price oversight risk into Big Pharma, especially Novo Nordisk and Eli Lilly, and into some banks and fintech. He also notes prediction markets Polymarket and Kalshi could be drawn into scrutiny, though public tradable exposure is less clear.
- Democratic midterm control likely shifts oversight toward private-sector subpoenas and CEO testimony.
- The strategy is described as naming-and-shaming to damage Trump rather than necessarily prosecuting companies.
- A Venn diagram of Trump ties and voter-visceral sectors flags Big Pharma as discount risk.
- Novo Nordisk and Eli Lilly are singled out for signing drug pricing deals with the administration.
- Some banks and fintech companies face similar oversight discount risk.
- Don Trump Jr.'s roles at Polymarket and Kalshi may draw prediction markets into scrutiny.
- Investors should price political oversight risk before the midterms.
Ideas
Big Pharma faces oversight discount risk.
If Democrats take at least one chamber, they will use private-sector oversight as a second track, targeting companies with Trump ties and voter backlash. Big Pharma is directly in that Venn diagram, and Democrats are likely to call CEOs from companies like Novo Nordisk and Eli Lilly that signed drug pricing deals with the administration, so investors should put a discount into these stocks now.
Banks and fintech face oversight risk.
Some financial services companies, particularly banks and fintech, fall in the same Venn diagram of close administration ties or self-protective contributions plus visceral voter reaction, making them likely targets for Democratic private-sector oversight and stock-price discounts.
